امروز : پنجشنبه 24 آبان 1397 Rss | صفحه اصلی دانشکده
3 مهر 1395

بررسی میزان بقا و عوامل پیش‌آگهی دهنده در مبتلایان به کارسینوم سلول سنگفرشی سر و گردن مراجعه کننده به انستیتو کانسر بیمارستان امام خمینی تهران طی سال‌های 1390-1384

بقای بیماران مبتلا به کارسینوم سلول سنگفرشی سروگردن تحت الشعاع عوامل مختلفی بوده و در نقاط مختلف جهان متفاوت است.در این مطالعه بر آن شدیم بقای و نیز عوامل پیش‌آگهی دهنده را در بیمارانی که جهت درمان‌های ابتدایی به انستیتو کانسر به عنوان قطب کانسر کشور، مراجعه کرده‌اند، بررسی کنیم. روش بررسی پژوهش انجام شده، مطالعه ای گذشته نگر و مبتنی بر بیمارستان است که به بررسی 483 مورد ابتلا کارسینوم سلول سنگفرشی سروگردن طی سال های 1390-1384 در مراجعین به انستیتو کانسر بیمارستان امام خمینی می پردازد. بعد از تهیه ی پرسشنامه و انجام پایلوت بر 20 مورد تصادفی از سال های 1385-1384 نسخه ی نهایی پرسشنامه ها تهیه شد که شامل  اطلاعات دموگرافیک، بقا و کلینیکو-پاتولوژیکال بیماران می شود. سپس پرونده های کموتراپی، رادیوتراپی و جراحی همه ی بیماران بستری شده در انستیتو کانسر طی 1 فروردین 1384 تا پایان اسفند 89 مشتمل بر 410 مورد و 73 مورد تصادفی از سال 1390 با تشخیص کارسینوم سلول سنگفرشی سروگردن جداسازی و در پرسشنامه ی اول وارد گردید. پرسشنامه ی دوم که به بررسی وضعیت بیماران بعد از درمان های اولیه پرداخته نیز از طریق برقراری تماس تلفنی با بیماران تکمیل شد. مجموع اطلاعات پرسشنامه ها در بانک اطلاعاتی مبتنی بر وب وارد و سپس از طریق نسخه ی دهم نرم افزار آماری STATA آنالیز شد.پیش بینی بقای بیماران بر اساس فاکتورهای مختلف نیز با روش آماری کاپلان-مایر و Cox-regression تبیین شد. نتایج در این پژوهش 483 بیمار مبتلا به کارسینوم سلول سنگفرشی سرو گردن در نواحی لب ها،حفره ی دهان، فارنکس، لارنکس، حفره ی بینی و سینوس های پارانازال و غدد بزاقی اصلی  که پیش از مراجعه به انستیتو کانسر، تحت درمان علاج بخش قرار نگرفته بودند و سابقه ی ابتلا به کارسینوم سلول سنگفرشی سروگردن نیز نداشتند،بررسی شدند. غالب تومورها در ناحیه ی حفره ی دهان و غالب بیماران مذکر بودند.گروه سنی غالب نیز موارد  70-50 ساله با اختصاص 39.34% از بیماران، گزارش شده است. برای بررسی روند مراجعه ی بیماران بعد از گسترش انستیتو کانسر در زمینه کانسرهای سروگردن، تعداد موارد مراجعه در سال های 1387-1384 و 1390-1388 تفکیک شده و مشاهده شد که 57.11% از موارد متعلق به سال های 1387-1384 بودند ولی تعداد مبتلایان به تومورهای حفره ی دهان،در دو بازه ی زمانی تقریبا برابر بوده است. 44.31% از کل تومورهای دارای تمایز خوب بوده اند در حالیکه تنها 4.14% تمایزیافتگی ضعیف گزارش شده است. 30.52% از تومورهای در مرحله ی IV و تنها 13.15% در مرحله ی I یا II قرار داشتند که حاکی از پیشرفته بودن تومورهای در زمان مراجعه دارد. میزان وقوع عود 34.96% و عدم وقوع 30.72% گزارش شده و در 34.32% از بیماران وضعیت وقوع عود نامشخص بوده است. هم چنین شایع ترین فرم عود موضعی-ناحیه ای گزارش شده است. میزان بقای کلی همه ی تومورهای بصورت 1، 3 و 5-ساله برابر 78% ، 46% و 36% گزارش شده است که بیشترین میزان بقای 5-ساله مربوط به تومورهای لب با 69% و کمترین میزان مربوط به تومورهای فارنکس با 10% بوده است. میزان بقای 1 و 5-ساله ی تومورهای لب-حفره ی دهانِ دارای مرحله ی پاتولوژیک مشخص نیز 85% و 43% گزارش شده است که در مراحل زودرس بیماری (I-II) 94% و 43% و در مراحل  پیشرفته (III-IV) 72% و 28% است. میزان بقای عاری از بیماری 1 و 5-ساله  نیز برای تومورهای لب-حفره ی دهان 60% و 26% گزارش شده است. نتیجه گیری در این پژوهش در بررسی ارتباط سن با بقای کلی همه ی مبتلایان ، بیماران کمتر از 50-سال بقای بیشتری از گروه های سنی دیگر داشتند که از نظر آماری قابل توجه نبوده است ولی سنین بالای 70-سال به لحاظ آماری بطور قابل توجهی با بقای بیماران مبتلا به تومورهای حفره ی دهان مرتبط بوده اند. صرف نظر از موارد نامشخص، در بررسی ارتباط بقای کلی با تحصیلات، بیماران دارای تحصیلات دیپلم و بالاتر نسبت به گروه فاقد تحصیلات، بقای بیشتری داشتند که از نظر آماری قابل توجه نبوده است. در بررسی بقای کلی مبتلایان به تومورهای لب و حفره ی دهان با گرید هیستولوژیک بیماری، میزان بقای بیماران با تومورهای خوب تمایز یافته نسبت به موارد دارای تمایز ضعیف بقای بیشتری داشتند. در بررسی ارتباط بقای کلی و مرحله ی بیماری تومورهای لب-حفره ی دهان در زمان تشخیص، مشاهده می شود که میزان بقای بیماران در مراحل زودرس، نسبت به مراحل پیشرفته واضحا بیشتر است که اهمیت آماری آن در آنالیز Cox-regression تایید می شود. كليد واژه ها : کارسینوم سلول سنگفرشی سروگردن- بقا-مرحله ی بیماری-گرید هیستولوژیک-تحصیلات-گروه های سنی مشخصات دانشجو: نام:مهتاب ملاشاهی   رشته تحصيلي:پزشکی مقطع:دکترای حرفه ای                     گروه آموزشي:اپیدمیولوژی(مرکز تحقیقات انستیتو کانسر بیمارستان امام خمینی)         پست الكترونيك دانشجو: mahtab.mshahi@yahoo.com اساتيد راهنما و داور: استاد راهنما:آقای دکتر کاظم زنده دل-خانم دکتر صنمبر صدیقی     اساتيد مشاور :آقای دکتر ایرج حریرچی   اساتيد داور:آقای دکتر محمد شیرخدا-خانم دکتر آذین نحوی جو زمان دفاع :    روز سه شنبه  تاريخ 95.6.23 ساعت 7.30 صبح مكان دفاع به آدرس: انتهای بلوار کشاورز-بیمارستان امام خمینی-انستیتو کانسر-طبقه ی سوم مرکز تحقیقات انستیتو کانسر-سالن شورا اطلاعات به زبان انگليسي Title: Evaluation of Survival and Prognostic Factors in Patients with Head and Neck Squamous Cell Carcinoma Referred to the Cancer Institute of Tehran Imam Khomeini Hospital During 1384-1390   Abstract: Background Survival of patients with head and neck squamous cell carcinoma (HNSS) is affected by several factors and varies in different countries. In this study we evaluate the survival and prognostic factors for pateinets with HNSCC referred to the Cancer Institute of Imam Khomeini Hosptital. Material and methods Current research as a hospital-based retro-spective study evaluate 483 patients with HNSCC referred to the Cancer Institute of Imam Khomeini Hosptital over 2004-2011. After preparing primary questionnaires and conducting a pilot study on 20 randomized cases of 2004-2005, final versions were developed which include demographic, survival and clinic-pathological information. Chemotherapy, radiotherapy and surgery files of 410 admitted HNSCC patients since April 2004 to March 2010 and 73 randomized cases of 2011 were separated and entered in the first questionnaire. The second questionnaire to assess the condition of patients after primary treatments was completed through phone calls. All gathered information was entered into a web-based database and analyzed through 10th version of STATA statistical software and survival models were predicted through Kaplan-Meier and cox-regression analysis.   Results Current study consists of 483 patients with SCC carcinoma of lips, oral cavity, pharynx, larynx, nasal cavity and paranasal sinuses and main salivary glands that didn't receive curative treatment for their cancers and didn’t have any history of previous HNSCC. Most of tumors were located in the oral cavity and most patients were male. The most prevalent age-group was 50-70 year old consisting 39.34% of all patients. According to the time of expansion of the Cancer Institute in the field of head and neck cancers study time was divided into two periods: 1384-1387 and 1388-1390. 57.11% of all patients referred to the Cancer Institute over 1384-1387 but number of patients with oral cavity tumors were almost the same. 44.31% of all tumors were well-differentiated while only 4.14% were poorly-differentiated. 30.52% of patients had stage IV disease and only 26.30% had stage I and II therefore most of them were advanced at the time of diagnosis. 34.96% and 30.72% of patients experienced and didn't experience recurrence respectively while 34.32% of cases had unknown status. 1 and 5-year overall survival for all patients was reported 78% and 36% respectively. The highest rate of 5-year overall survival was reported 69% for lip tumors and the least rate was 10% for pharyngeal tumors. 1 and 5-year overall survival rate for lip and oral cavity tumors with known pathologic stage, was reported 85% and 43% that is respectively 94% and 43% for ealy stage (I-II) and 72% and 28% for advanced stage tumors. 1 and 5-year disease free survival for lip and oral cavity tumors were reported 60% and 26% respectively. Conclusion In current study, age-group and survival rate was evaluated; patients age less than 50 year old had better overall survival than older patients while it was significant in patients older than 70 year old. Education-level and survival rate was assessed; regardless of cases with unknown level of education, patients with diploma and higher degrees had higher rate of overall survival than other groups but it was'nt statistically significant. According to the histologic grade, patients with well differentiated tumors had better overall survival than poorly-differentiated tumors. Correlation between overall survival and pathologic stage at the time of diagnosis was studied; survival rate was higher in early stages than advanced stages and its significance is cinfirmed through cox-regression anlysis.   Keywords: Head and neck squamous cell carcinoma-survival-pathologic stage-histologic grade-education level-age group   فهرست منابع و ماخذ فارسي و لاتين:   1.       Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA: A Cancer Journal for Clinicians. 2005;55(2):74-108. 2.       Levine PA SD. Neoplasms of the oral cavity. Bailey BJ, (ed) Head and Neck Surgery - Otolaryngology Lippincott-Raven Publishers , Philadelphia, PA. 1993:pp 1523–39. 3.       Seikaly H RC. Oropharyngeal cancer. In: Bailey BJ, (ed) Head and Neck Surgery – Otolaryngology Lippincott-Raven Publishers, Philadelphia, PA. 1998:1655–71. 4.       Schechter GL WT. Hypopharyngeal cancer. In: Bailey BJ , (ed) Head and Neck Surgery – Otolaryngology Lippincott-Raven Publishers , Philadelphia, PA. 1998,:1673–91. 5.       Fried MP GH, Frankenthaler R. Advanced cancer of the larynx. In: Bailey BJ (ed) Head and Neck Surgery – Otolaryngology Lippincott-Raven Publishers, Philadelphia, PA. 1998:1739–58. 6.       Collins S. Squamous cell carcinoma of the oral cavity, oropharynx, pharyngeal wall, and nasopharynx. In: Ballenger JJ, Snow JB (eds) Otorhinolaryngology – Head and Neck Surgery Williams & Wilkins, Media, PA. 1996:249–368. 7.       Kadeh H, Saravani S, Moradbeiki B. Epidemiological aspects of head and neck cancers in a population of south east region of Iran. Caspian Journal of Dental Research. 2015;4(2):33-9. 8.       Rad M, Chamani G, Zarei M, Hashemipour M. Epidemiological aspects of head and neck cancers in a group of Iranian population. Journal of Dentistry, Shiraz University of Medical Sciences. 2010;10:50-6. 9.       Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr. 2013. 10.     Andisheh-Tadbir A, Ashraf M, Jafari-Ashkavandi Z, Paknahad M, Taheri F. Head and neck squamous cell carcinoma in Southern Iran. Iranian Red Crescent Medical Journal. 2008;2008(4):309-13. 11.     Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Annals of oncology. 2009;20(3):556-63. 12.     Silverman S. Oral cancer: PMPH-USA; 2003. 13.     Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians. 2005;55(2):74-108. 14.     Moore S, Johnson N, Pierce A, Wilson D. The epidemiology of mouth cancer: a review of global incidence. Oral diseases. 2000;6(2):65-74. 15.     Nair U, Bartsch H, Nair J. Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms. Mutagenesis. 2004;19(4):251-62. 16.     Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse S, et al. SEER Cancer Statistics Review, 1975-2010.[Based on the November 2012 SEER data submission, posted to the SEER web site, April 2013.]. Bethesda, MD: National Cancer Institute. 2013. 17.     Novin K, Ameri A, Faraji S, Torbati P, Mortazavi N. Head and Neck Squamous Cell Carcinoma in Iran: Clinico-Pathological and Treatment-Related Factors Influencing Survival. Iranian journal of cancer prevention. 2015;8(5). 18.     Sargeran K. Oral Cancer in Tehran, Iran: An approach for understanding disease burden [Thesis]. Helsinki, Finland: School of Medicine, University of Helsinki. 2008. 19.     Mafi N, Kadivar M, Hosseini N, Ahmadi S, Zare-Mirzaie A. Head and neck squamous cell carcinoma in Iranian patients and risk factors in young adults: a fifteen-year study. Asian Pacific Journal of Cancer Prevention. 2012;13(7):3373-8. 20.     Latifi H, Mikaili P, Latifi K, Torbati H. Squamous cell carcinoma of larynx in northwestern Iran. Euro J Exp Bio. 2012;2(1):242-6. 21.     Simard EP, Torre LA, Jemal A. International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. Oral Oncol. 2014;50(5):387-403. 22.     Thun M, Peto R, Boreham J, Lopez AD. Stages of the cigarette epidemic on entering its second century. Tobacco Control. 2012;21(2):96-101. 23.     Divi V, Ma Y, Rhoads KF. Regional variation in head and neck cancer mortality: Role of patient and hospital characteristics. Head & neck. 2015. 24.     Sarris EG, Harrington KJ, Saif MW, Syrigos KN. Multimodal treatment strategies for elderly patients with head and neck cancer. Cancer Treat Rev. 2014;40(3):465-75. 25.     Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22(22):4626-31. 26.     Bhattacharyya N. A matched survival analysis for squamous cell carcinoma of the head and neck in the elderly. Laryngoscope. 2003;113(2):368-72. 27.     Siddiqui F, Gwede CK. Head and neck cancer in the elderly population. Semin Radiat Oncol. 2012;22(4):321-33. 28.     Stenson KM, Kunnavakkam R, Cohen EE, Portugal LD, Blair E, Haraf DJ, et al. Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope. 2010;120(1):93-9. 29.     Turner SL SN, Gupta NK et al.  . Radical external beam radiotherapy for 333 squamous carcinomas of the oral cavity—evaluation of late morbidity and a watch policy for the clinically negative neck. Radiother Oncol. 1996;41:21–9. 30.     Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer. 2005;114(5):806-16. 31.     Ferlay J, al. e. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. Lyon. IARC Press. 2004. 32.     Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians. 2015;65(2):87-108. 33.     Curado MP, Hashibe M. Recent changes in the epidemiology of head and neck cancer. Curr Opin Oncol. 2009;21(3):194-200. 34.     Hammarstedt L, Dahlstrand H, Lindquist D, Onelov L, Ryott M, Luo J, et al. The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol. 2007;127(9):988-92. 35.     Junor EJ, Kerr GR, Brewster DH. Oropharyngeal cancer. Fastest increasing cancer in Scotland, especially in men: BMJ. 2010 May 11;340:c2512. doi: 10.1136/bmj.c2512. 36.     Conway DI, Stockton DL, Warnakulasuriya KA, Ogden G, Macpherson LM. Incidence of oral and oropharyngeal cancer in United Kingdom (1990-1999) -- recent trends and regional variation. Oral Oncol. 2006;42(6):586-92. 37.     Sharpe KH, McMahon AD, McClements P, Watling C, Brewster DH, Conway DI. Socioeconomic inequalities in incidence of lung and upper aero-digestive tract cancer by age, tumour subtype and sex: a population-based study in Scotland (2000-2007). Cancer Epidemiol. 2012;36(3):20. 38.     Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26(4):612-9. 39.     Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence. Cancer. 2007;110(7):1429-35. 40.     Gillison ML, Alemany L, Snijders PJF, Chaturvedi A, Steinberg BM, Schwartz S, et al. Human Papillomavirus and Diseases of the Upper Airway: Head and Neck Cancer and Respiratory Papillomatosis. Vaccine. 2012;30, Supplement 5:F34-F54. 41.     Cooper JS, Porter K, Mallin K, Hoffman HT, Weber RS, Ang KK, et al. National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck. 2009;31(6):748-58. 42.     Gorsky M, Epstein JB, Oakley C, Le ND, Hay J, Stevenson-Moore P. Carcinoma of the tongue: a case series analysis of clinical presentation, risk factors, staging, and outcome. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 2004;98(5):546-52. 43.     Warnakulasuriya K, Ralhan R. Clinical, pathological, cellular and molecular lesions caused by oral smokeless tobacco–a review. Journal of oral pathology & medicine. 2007;36(2):63-77. 44.     Merino OR, Lindberg RD, Fletcher GH. An analysis of distant metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer. 1977;40(1):145-51. 45.     Panosetti E LB, Marmelle G, Richard JM. . Multiple synchronous and metachronous cancers of the upper autodigestive tract: a nineyear study. . Laryngoscope 1989;99.:1267-73. 46.     Wolf G LS, Laramore G, et al: :. Head and neck cancer, in Holland JF, Frei E, Bast RC Jr, et al (eds). Cancer Medicine, 3rd ed, Philadelphia, Lea & Febiger. 1993:1211-78. 47.     Million R, Cassisi, NJ, Clark, JR. Cancer of the head and neck. in: De Vita VT Jr, Hellman S, Rosenberg SA (Eds.). Cancer Principles and Practice of Oncology JB Lippincott, Philadelphia; . 1989:488-590. 48.     Slaughter DP, Southwick HW, Smejkal W. “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer. 1953;6(5):963-8. 49.     Vokes  EE, Weichselbaum  RR, Lippman  SM, Hong  WK. Head and Neck Cancer. New England Journal of Medicine. 1993;328(3):184-94. 50.     Sadri D, Azizi A, Farhadi S, Shokrgozar H, Entezari N. Head and neck metastatic tumors: a retrospective survey of Iranian patients. Journal of Dentistry. 2015;16(1):17. 51.     Rettig EM, D’Souza G. Epidemiology of Head and Neck Cancer. Surgical Oncology Clinics.24(3):379-96. 52.     Schlecht NF, Franco EL, Pintos J, Kowalski LP. Effect of smoking cessation and tobacco type on the risk of cancers of the upper aero-digestive tract in Brazil. Epidemiology. 1999;10(4):412-8. 53.     Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer research. 1988;48(11):3282-7. 54.     Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, et al. Alcohol Drinking in Never Users of Tobacco, Cigarette Smoking in Never Drinkers, and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. Journal of the National Cancer Institute. 2007;99(10):777-89. 55.     Vineis P, Alavanja M, Buffler P, Fontham E, Franceschi S, Gao YT, et al. Tobacco and Cancer: Recent Epidemiological Evidence. Journal of the National Cancer Institute. 2004;96(2):99-106. 56.     Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, et al. A review of human carcinogens&#x2014;Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. The lancet oncology.10(11):1033-4. 57.     Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. The lancet oncology.9(7):667-75. 58.     Zhou J, Michaud DS, Langevin SM, McClean MD, Eliot M, Kelsey KT. Smokeless tobacco and risk of head and neck cancer: Evidence from a case–control study in New England. International journal of cancer. 2013;132(8):1911-7. 59.     Sturgis EM, Wei Q, Spitz MR. Descriptive epidemiology and risk factors for head and neck cancer. Semin Oncol. 2004;31(6):726-33. 60.     Anantharaman D, Marron M, Lagiou P, Samoli E, Ahrens W, Pohlabeln H, et al. Population attributable risk of tobacco and alcohol for upper aerodigestive tract cancer. Oral Oncology.47(8):725-31. 61.     Hashibe M, Boffetta P, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Mates D, et al. Contribution of Tobacco and Alcohol to the High Rates of Squamous Cell Carcinoma of the Supraglottis and Glottis in Central Europe. American Journal of Epidemiology. 2007;165(7):814-20. 62.     Simard EP, Torre LA, Jemal A. International trends in head and neck cancer incidence rates: Differences by country, sex and anatomic site. Oral Oncology.50(5):387-403. 63.     Begum S, Cao D, Gillison M, Zahurak M, Westra WH. Tissue Distribution of Human Papillomavirus 16 DNA Integration in Patients with Tonsillar Carcinoma. American Association for Cancer Research. 2005;11(16):5694-9. 64.     Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a Causal Association Between Human Papillomavirus and a Subset of Head and Neck Cancers. Journal of the National Cancer Institute. 2000;92(9):709-20. 65.     Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct Risk Factor Profiles for Human Papillomavirus Type 16–Positive and Human Papillomavirus Type 16–Negative Head and Neck Cancers. Journal of the National Cancer Institute. 2008;100(6):407-20. 66.     Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved Survival of Patients With Human Papillomavirus–Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial. Journal of the National Cancer Institute. 2008;100(4):261-9. 67.     Ang  KK, Harris  J, Wheeler  R, Weber  R, Rosenthal  DI, Nguyen-Tân  PF, et al. Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. New England Journal of Medicine. 2010;363(1):24-35. 68.     Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States. Journal of Clinical Oncology. 2011;29(32):4294-301. 69.     Lin BM, Wang H, D'Souza G, Zhang Z, Fakhry C, Joseph AW, et al. Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma. Cancer. 2013;119(19):3462-71. 70.     Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, et al. Molecular Classification Identifies a Subset of Human Papillomavirus–Associated Oropharyngeal Cancers With Favorable Prognosis. Journal of Clinical Oncology. 2006;24(5):736-47. 71.     Lewis JSJ, Thorstad WL, Chernock RD, Haughey BH, Yip JH, Zhang Q, et al. p16 Positive Oropharyngeal Squamous Cell Carcinoma:An Entity With a Favorable Prognosis Regardless of Tumor HPV Status. The American Journal of Surgical Pathology. 2010;34(8):1088-96. 72.     Mehanna H, Beech T, Nicholson T, El‐Hariry I, McConkey C, Paleri V, et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta‐analysis of trends by time and region. Head & neck. 2013;35(5):747-55. 73.     Park K, Cho KJ, Lee M, Yoon DH, Kim J, Kim SY, et al. p16 immunohistochemistry alone is a better prognosticator in tonsil cancer than human papillomavirus in situ hybridization with or without p16 immunohistochemistry. Acta Oto-Laryngologica. 2013;133(3):297-304. 74.     Lingen MW, Xiao W, Schmitt A, Jiang B, Pickard R, Kreinbrink P, et al. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncology.49(1):1-8. 75.     Tota JE, Chevarie-Davis M, Richardson LA, deVries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. Preventive Medicine. 2011;53, Supplement 1:S12-S21. 76.     Herrero R, Castellsagué X, Pawlita M, Lissowska J, Kee F, Balaram P, et al. Human Papillomavirus and Oral Cancer: The International Agency for Research on Cancer Multicenter Study. Journal of the National Cancer Institute. 2003;95(23):1772-83. 77.     Gillison ML, Broutian T, al e. Prevalence of oral HPV infection in the United States, 2009-2010. Jama. 2012;307(7):693-703. 78.     Mork  J, Lie  AK, Glattre  E, Clark  S, Hallmans  G, Jellum  E, et al. Human Papillomavirus Infection as a Risk Factor for Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine. 2001;344(15):1125-31. 79.     Kreimer AR, Johansson M, Waterboer T, Kaaks R, Chang-Claude J, Drogen D, et al. Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer. Journal of Clinical Oncology. 2013;31(21):2708-15. 80.     Sanderson RJ, Ironside JAD. Squamous cell carcinomas of the head and neck. BMJ : British Medical Journal. 2002;325(7368):822-7. 81.     Excellence NIfC. Guidance on cancer services: improving outcomes in head and neck cancers: the manual: National Institute for Clinical Excellence; 2004. 82.     Castelijns JA. Diagnostic radiology in head and neck oncology. Curr Opin Oncol. 1990;2(3):557-61. 83.     Frederick L, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. AJCC cancer staging manual: Springer Science & Business Media; 2002. 84.     Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328(3):184-94. 85.     Stokkel MPM, ten Broek F-W, Hordijk G-J, Koole R, van Rijk PP. Preoperative Evaluation of Patients With Primary Head and Neck Cancer Using Dual-Head (18)Fluorodeoxyglucose Positron Emission Tomography. Annals of Surgery. 2000;231(2):229-34. 86.     Ribeiro KC, Kowalski LP, Latorre MR. Impact of comorbidity, symptoms, and patients' characteristics on the prognosis of oral carcinomas. Arch Otolaryngol Head Neck Surg. 2000;126(9):1079-85. 87.     Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of surgical oncology. 2010;17(6):1471-4. 88.     Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM: Ann Surg Oncol. 2010 Jun;17(6):1471-4. doi: 10.1245/s10434-010-0985-4. 89.     Pfister D, Ang K, Brockstein B, Colevas A, Ellenhorn J, Goepfert H, et al. NCCN practice guidelines for head and neck cancers. Oncology (Williston Park, NY). 2000;14(11A):163. 90.     Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, et al. Head and neck cancers, version 1.2015. Journal of the National Comprehensive Cancer Network. 2015;13(7):847-56. 91.     Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21-8. 92.     Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4-14. 93.     Lowe VJ, Boyd JH, Dunphy FR, Kim H, Dunleavy T, Collins BT, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol. 2000;18(3):651-8. 94.     Alex JC, Sasaki CT, Krag DN, Wenig B, Pyle PB. Sentinel lymph node radiolocalization in head and neck squamous cell carcinoma. Laryngoscope. 2000;110(2 Pt 1):198-203. 95.     Calabrese L, Bruschini R, Ansarin M, Giugliano G, De Cicco C, Ionna F, et al. Role of sentinel lymph node biopsy in oral cancer. Acta Otorhinolaryngologica Italica. 2006;26(6):345-9. 96.     Scully C, Bagan JV. Recent advances in oral oncology 2008; squamous cell carcinoma imaging, treatment, prognostication and treatment outcomes. Oral Oncology. 2009;45(6):e25-e30. 97.     Scully C, Bagan J. Oral squamous cell carcinoma overview. Oral Oncology. 2009;45(4):301-8. 98.     Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. International journal of cancer. 2001;94(2):153-6. 99.     Hoffman HT, Karnell L, Funk GF, Robinson RA, Menck HR. THe national cancer data base report on cancer of the head and neck. Archives of Otolaryngology–Head & Neck Surgery. 1998;124(9):951-62. 100.   Roland NJ, Caslin AW, Nash J, Stell PM. Value of grading squamous cell carcinoma of the head and neck. Head & neck. 1992;14(3):224-9. 101.   Nakashima T, Maehara Y, Kohnoe S, Hayashi I, Katsuta Y. Histologic differentiation and chemosensitivity of human head and neck squamous cell carcinomas. Head & neck. 1990;12(5):406-10. 102.   Crissman JD, Pajak TF, Zarbo R, Marcial V, Al-Sarraf M. Improved response and survival to combined cisplatin and radiation in non-keratinizing squamous cell carcinomas of the head and neck. Cancer. 1987;59(8):1391-7. 103.   Ensley J, Maciorowski Z, Pietraszkiewicz H, Hassan M, Kish J, Al‐Sarraf M, et al. Solid tumor preparation for clinical application of flow cytometry. Cytometry. 1987;8(5):488-93. 104.   Ensley JF, Kish JA, Weaver AA, Jacobs JR, Hassan M, Cummings G, et al. The correlation of specific variables of tumor differentiation with response rate and survival in patients with advanced head and neck cancer treated with induction chemotherapy. Cancer. 1989;63(8):1487-92. 105.   Bradford C, Poore J, Wilson M, CAREY T, McCLATCHEY K, WOLF G. Biological markers which predict response to chemotherapy in head and neck cancer. Biology, Prevention and Treatment of Head and Neck Cancer HN. 1994;149. 106.   Datema FR, Ferrier MB, van der Schroeff MP, Baatenburg de Jong RJ. Impact of comorbidity on short-term mortality and overall survival of head and neck cancer patients. Head Neck. 2010;32(6):728-36. 107.   Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001;345(26):1890-900. 108.   Coleman MP, Gatta G, Verdecchia A, Esteve J, Sant M, Storm H, et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol. 2003;128(14). 109.   Wise-Draper TM, Draper DJ, Gutkind JS, Molinolo AA, Wikenheiser-Brokamp KA, Wells SI. Future Directions and Treatment Strategies for Head and Neck Squamous Cell Carcinomas. Translational research : the journal of laboratory and clinical medicine. 2012;160(3):167-77. 110.   Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9-22. 111.   Sano D, Myers JN. Xenograft models of head and neck cancers. Head & Neck Oncology. 2009;1:32-. 112.   Sethi S, Ali-Fehmi R, Franceschi S, Struijk L, van Doorn LJ, Quint W, et al. Characteristics and survival of head and neck cancer by HPV status: a cancer registry-based study. Int J Cancer. 2012;131(5):1179-86. 113.   Marur S, Forastiere AA, editors. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clinic Proceedings; 2008: Elsevier. 114.   Pfister DG, Ang K-K, Brizel DM, Burtness BA, Busse PM, Caudell JJ, et al. Head and neck cancers, version 2.2013. Journal of the National Comprehensive Cancer Network. 2013;11(8):917-23. 115.   Marur S, Forastiere AA. Update on role of chemotherapy in head and neck squamous cell cancer. Indian Journal of Surgical Oncology. 2010;1(2):85-95. 116.   Lorch JH, Posner MR, Wirth LJ, Haddad RI. Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? Hematol Oncol Clin North Am. 2008;22(6):1155-63. 117.   Schmitz S, Ang KK, Vermorken J, Haddad R, Suarez C, Wolf GT, et al. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions. Cancer Treat Rev. 2014;40(3):390-404. 118.   Kofler B, Laban S, Busch C, Lörincz B, Knecht R. New treatment strategies for HPV-positive head and neck cancer. European archives of oto-rhino-laryngology. 2014;271(7):1861-7. 119.   Adelstein DJ, Ridge JA, Brizel DM, Holsinger FC, Haughey BH, O'Sullivan B, et al. Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia. Head Neck. 2012;34(12):1681-703. 120.   Arens C. Transoral treatment strategies for head and neck tumors. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2012;11(10):20. 121.   Cohen MA, Weinstein GS, O'Malley BW, Feldman M, Quon H. Transoral robotic surgery and human papillomavirus status: oncologic results. Head & neck. 2011;33(4):573-80. 122.   Robbins KT, Shaha AR, Medina JE, Califano JA, Wolf GT, Ferlito A, et al. Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg. 2008;134(5):536-8. 123.   Northrop MF FG, Jesse RH, Lindberg RP. . Evolution of neck disease in patients with primary squamous cell carcinoma of the oral tongue, floor of mouth and palatine arch and clinically positive neck nodes neither fixed nor bilateral. Cancer. 1972;29:23-30. 124.   Byers RM. Neck dissection: concepts, controversies, and technique. Semin Surg Oncol. 1991;7(1):9-13. 125.   Stringer SP. Current concepts in surgical management of neck metastases from head and neck cancer. Oncology. 1995;9(6):547-54. 126.   Candela FC, Kothari K, Shah JP. Patterns of cervical node metastases from squamous carcinoma of the oropharynx and hypopharynx. Head Neck. 1990;12(3):197-203. 127.   Candela FC, Shah J, Jaques DP, Shah JP. Patterns of cervical node metastases from squamous carcinoma of the larynx. Arch Otolaryngol Head Neck Surg. 1990;116(4):432-5. 128.   Shah JP, Candela FC, Poddar AK. The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. Cancer. 1990;66(1):109-13. 129.   Ferlito A, Rinaldo A, Silver CE, Gourin CG, Shah JP, Clayman GL, et al. Elective and therapeutic selective neck dissection. Oral Oncol. 2006;42(1):14-25. 130.   Schmitz S, Machiels JP, Weynand B, Gregoire V, Hamoir M. Results of selective neck dissection in the primary management of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2009;266(3):437-43. 131.   Patel RS, Clark J, Wyten R, Gao K, O'Brien CJ. Squamous cell carcinoma from an unknown head and neck primary site: a "selective treatment" approach. Arch Otolaryngol Head Neck Surg. 2007;133(12):1282-7. 132.   Sivanandan R, Kaplan MJ, Lee KJ, Lebl D, Pinto H, Le QT, et al. Long-term results of 100 consecutive comprehensive neck dissections: implications for selective neck dissections. Arch Otolaryngol Head Neck Surg. 2004;130(12):1369-73. 133.   Harrison LB, Sessions RB, Hong WK. Head and neck cancer: a multidisciplinary approach: Lippincott Williams & Wilkins; 2009. 134.   Cellai E, Frata P, Magrini SM, Paiar F, Barca R, Fondelli S, et al. Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1N0 disease. Int J Radiat Oncol Biol Phys. 2005;63(5):1378-86. 135.   Fein DA, Mendenhall WM, Parsons JT, Million RR. T1-T2 squamous cell carcinoma of the glottic larynx treated with radiotherapy: a multivariate analysis of variables potentially influencing local control. Int J Radiat Oncol Biol Phys. 1993;25(4):605-11. 136.   Nishimura Y, Nagata Y, Okajima K, Mitsumori M, Hiraoka M, Masunaga S-i, et al. Radiation therapy for T1, 2 glottic carcinoma: impact of overall treatment time on local control. Radiotherapy and Oncology. 1996;40(3):225-32. 137.   Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. New England Journal of Medicine. 2003;349(22):2091-8. 138.   Lefebvre J-L, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. Journal of the National Cancer Institute. 1996;88(13):890-9. 139.   Wolf GT, Hong WK, Fisher SG, Urba S, Endicott JW, Close L, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. New England Journal of Medicine. 1991;324(24):1685-90. 140.   Levendag PC, Teguh DN, Voet P, van der Est H, Noever I, de Kruijf WJ, et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiotherapy and Oncology. 2007;85(1):64-73. 141.   Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. Journal of Clinical Oncology. 2008;26(21):3582-9. 142.   Chao KC, Majhail N, Huang C-j, Simpson JR, Perez CA, Haughey B, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiotherapy and Oncology. 2001;61(3):275-80. 143.   Gupta T, Agarwal J, Jain S, Phurailatpam R, Kannan S, Ghosh-Laskar S, et al. Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. Radiotherapy and Oncology. 2012;104(3):343-8. 144.   Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. The lancet oncology. 2011;12(2):127-36. 145.   Kam MK, Leung S-F, Zee B, Chau RM, Suen JJ, Mo F, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. Journal of Clinical Oncology. 2007;25(31):4873-9. 146.   Peng G, Wang T, Yang K-y, Zhang S, Zhang T, Li Q, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiotherapy and Oncology. 2012;104(3):286-93. 147.   Marta GN, Silva V, de Andrade Carvalho H, de Arruda FF, Hanna SA, Gadia R, et al. Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis. Radiother Oncol. 2014;110(1):9-15. 148.   Roe JW, Carding PN, Dwivedi RC, Kazi RA, Rhys-Evans PH, Harrington KJ, et al. Swallowing outcomes following Intensity Modulated Radiation Therapy (IMRT) for head & neck cancer - a systematic review. Oral Oncol. 2010;46(10):727-33. 149.   Scott-Brown M, Miah A, Harrington K, Nutting C. Evidence-based review: quality of life following head and neck intensity-modulated radiotherapy. Radiother Oncol. 2010;97(2):249-57. 150.   Klein J, Livergant J, Ringash J. Health related quality of life in head and neck cancer treated with radiation therapy with or without chemotherapy: a systematic review. Oral Oncol. 2014;50(4):254-62. 151.   Tribius S, Bergelt C. Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: is there a worthwhile quality of life gain? Cancer treatment reviews. 2011;37(7):511-9. 152.   Pigneux J, Richaud PM, Lagarde C. The place of interstitial therapy using 192 iridium in the management of carcinoma of the lip. Cancer. 1979;43(3):1073-7. 153.   Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. Journal of Clinical Oncology. 2004;22(9):1743-52. 154.   Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Journal of Clinical Oncology. 2006;24(17):2644-52. 155.   De Andres L, Brunet J, Lopez-Pousa A, Burgués J, Vega M, Tabernero JM, et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. Journal of Clinical Oncology. 1995;13(6):1493-500. 156.   Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. Journal of Clinical Oncology. 1992;10(8):1245-51. 157.   Jeremic B, Shibamoto Y, Stanisavljevic B, Milojevic L, Milicic B, Nikolic N. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiotherapy and Oncology. 1997;43(1):29-37. 158.   Holoye PY, Grossman TW, Toohill RJ, Kun LE, Byhardt RW, Duncavage JA, et al. Randomized study of adjuvant chemotherapy for head and neck cancer. Otolaryngol Head Neck Surg. 1985;93(6):712-7. 159.   Taylor S, Applebaum E, Showel J, Norusis M, Holinger L, Hutchinson J, et al. A randomized trial of adjuvant chemotherapy in head and neck cancer. Journal of Clinical Oncology. 1985;3(5):672-9. 160.   Rentschler RE, Wilbur D, Petti G, Chonkich G, Hilliard D, Camacho E, et al. Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas--a prospective, randomized study. Journal of Clinical Oncology. 1987;5(2):278-85. 161.   Laramore GE, Scott C, Al-Sarraf M, Haselow R, Ervin T, Wheeler R, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report of intergroup study 0034. International Journal of Radiation Oncology* Biology* Physics. 1992;23(4):705-13. 162.   Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Hernandez JJC, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. Journal of Clinical Oncology. 2013;31(23):2854-60. 163.   Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. The lancet oncology. 2015;16(2):221-32. 164.   Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324(24):1685-90. 165.   Newkirk KA, Cullen KJ, Harter KW, Picken CA, Sessions RB, Davidson BJ. Planned neck dissection for advanced primary head and neck malignancy treated with organ preservation therapy: disease control and survival outcomes. Head Neck. 2001;23(2):73-9. 166.   Caponigro F, Massa E, Rosati G, Biglietto M, De Lucia L, Sguotti C, et al. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG). Annals of oncology. 2001;12(2):199-202. 167.   Urken ML, Buchbinder D, Costantino PD, Sinha U, Okay D, Lawson W, et al. Oromandibular reconstruction using microvascular composite flaps: report of 210 cases. Arch Otolaryngol Head Neck Surg. 1998;124(1):46-55. 168.   Lyos AT, Evans GR, Perez D, Schusterman MA. Tongue reconstruction: outcomes with the rectus abdominis flap. Plast Reconstr Surg. 1999;103(2):442-7. 169.   Bernier  J, Domenge  C, Ozsahin  M, Matuszewska  K, Lefèbvre  J-L, Greiner  RH, et al. Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer. New England Journal of Medicine. 2004;350(19):1945-52. 170.   Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937-44. 171.   Kiyota N, Tahara M, Fujii M. Adjuvant treatment for post-operative head and neck squamous cell carcinoma. Japanese journal of clinical oncology. 2015;45(1):2-6. 172.   Merlano M, Benasso M, Corvò R, Rosso R, Vitale V, Blengio F, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. Journal of the National Cancer Institute. 1996;88(9):583-9. 173.   Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, et al. An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer. Journal of Clinical Oncology. 2003;21(1):92-8. 174.   Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998;16(4):1318-24. 175.   Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338(25):1798-804. 176.   Hamoir M, Schmitz S, Holvoet E, Ambroise J, Lengele B. 2848 Salvage surgery in recurrent head and neck squamous cell carcinoma. Oncologic outcome and prognostic factors. European Journal of Cancer. 2015;51:S573. 177.   Deeken JF, Newkirk K, Harter KW, Marshall MB, Banovac F, Johnson L, et al. Effect of multimodality treatment on overall survival for patients with metastatic or recurrent HPV-positive head and neck squamous cell carcinoma. Head & neck. 2015;37(5):630-5. 178.   Romesser PB, Cahlon O, Scher ED, Hug EB, Sine K, DeSelm C, et al. Proton Beam Reirradiation for Recurrent Head and Neck Cancer: Multi-institutional Report on Feasibility and Early Outcomes. Int J Radiat Oncol Biol Phys. 2016;95(1):386-95. 179.   Colevas AD. Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology. 2006;24(17):2644-52. 180.   Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116-27. 181.   Brockstein B, Haraf D, Rademaker A, Kies M, Stenson K, Rosen F, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Annals of oncology. 2004;15(8):1179-86. 182.   Pignon J-P, Le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiotherapy and Oncology. 2009;92(1):4-14. 183.   León X, Quer M, Diez S, Orús C, López‐Pousa A, Burgués J. Second neoplasm in patients with head and neck cancer. Head & neck. 1999;21(3):204-10. 184.   Warren S. Multiple primary malignant tumors. Am J cancer. 1932;16:1358-414. 185.   Sturgis EM, Miller RH. Second primary malignancies in the head and neck cancer patient. Annals of Otology, Rhinology & Laryngology. 1995;104(12):946-54. 186.   Cooper JS, Pajak TF, Rubin P, Tupchong L, Brady LW, Leibel SA, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. International Journal of Radiation Oncology* Biology* Physics. 1989;17(3):449-56. 187.   Takes RP, Rinaldo A, Silver CE, Haigentz M, Woolgar JA, Triantafyllou A, et al. Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspects. Oral Oncology. 2012;48(9):775-9. 188.   Denaro N, Merlano MC, Russi EG. Follow-up in Head and Neck Cancer: Do More Does It Mean Do Better? A Systematic Review and Our Proposal Based on Our Experience. Clinical and Experimental Otorhinolaryngology. 2016. 189.   Colevas AD, Read R, Thornhill J, Adak S, Tishler R, Busse P, et al. Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2001;51(3):599-604. 190.   Tell R, Lundell G, Nilsson B, Sjodin H, Lewin F, Lewensohn R. Long-term incidence of hypothyroidism after radiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;60(2):395-400. 191.   Posner MR, Ervin TJ, Miller D, Fabian RL, Norris CM, Jr., Weichselbaum RR, et al. Incidence of hypothyroidism following multimodality treatment for advanced squamous cell cancer of the head and neck. Laryngoscope. 1984;94(4):451-54. 192.   Mamelle G, Pampurik J, Luboinski B, Lancar R, Lusinchi A, Bosq J. Lymph node prognostic factors in head and neck squamous cell carcinomas. The American journal of surgery. 1994;168(5):494-8. 193.   O'Brien CJ, Smith JW, Soong S-J, Urist MM, Maddox WA. Neck dissection with and without radiotherapy: prognostic factors, patterns of recurrence, and survival. The American journal of surgery. 1986;152(4):456-63. 194.   Snow G, Annyas A, Slooten Ev, Bartelink H, Hart A. Prognostic factors of neck node metastasis. Clinical Otolaryngology & Allied Sciences. 1982;7(3):185-92. 195.   Wei WI. Commentary: head and neck carcinomas in the developing world. British Medical Journal. 2002. 196.   Wünsch-Filho V, de Camargo EA, editors. The burden of mouth cancer in Latin America and the Caribbean: epidemiologic issues. Seminars in oncology; 2001: Elsevier. 197.   Wei W. Management of early carcinoma of the larynx, the Asian perspective. ENT News. 2000. 198.   de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur J Cancer. 2001;37(3):332-9. 199.   Pulte D, Brenner H. Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis. The Oncologist. 2010;15(9):994-1001. 200.   Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917. 201.   Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300. 202.   Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians. 2011;61(2):69-90. 203.   Licitra L, Locati LD, Bossi P, Cantu G. Head and neck tumors other than squamous cell carcinoma. Curr Opin Oncol. 2004;16(3):236-41. 204.   Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29. 205.   Joshi A, Calman F, O'Connell M, Jeannon J-P, Pracy P, Simo R. Current trends in the follow-up of head and neck cancer patients in the UK. Clinical Oncology. 2010;22(2):114-8. 206.   Nikakhlagh S, Saki N, shoar MH, Sartipipor A, Saki S. Incidence of Etiologic Factors in Squamous Cell Carcinoma of Head and Neck in Ahvaz. Iranian Journal of Otorhinolaryngology. 2012;24(67):85-90. 207.   Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45(4-5):309-16. 208.   Conway DI, Brenner DR, McMahon AD, Macpherson LM, Agudo A, Ahrens W, et al. Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case-control studies from 27 countries. Int J Cancer. 2015;136(5):1125-39. 209.   Cavelaars AEJM, Kunst AE, Geurts JJM, Crialesi R, Grötvedt L, Helmert U, et al. Educational differences in smoking: international comparison. BMJ. 2000;320(7242):1102-7. 210.   Current cigarette smoking among adults - United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61(44):889-94. 211.   Boing AF, Antunes JLF, de Carvalho MB, de Góis Filho JF, Kowalski LP, Michaluart P, et al. How much do smoking and alcohol consumption explain socioeconomic inequalities in head and neck cancer risk? Journal of Epidemiology and Community Health. 2011;65(8):709-14. 212.   Menvielle G, Luce D, Goldberg P, Leclerc A. Smoking, alcohol drinking, occupational exposures and social inequalities in hypopharyngeal and laryngeal cancer. International Journal of Epidemiology. 2004;33(4):799-806. 213.   Day MS. Late presentation, late diagnosis, late stage diagnosis, delayed diagnosis, delayed presentation: terminology confuses the message in UK cancer policy. BMJ. 2012;344. 214.   Vermorken J, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Annals of oncology. 2010;21(suppl 7):vii252-vii61. 215.   Ferlito A, Takes RP, Silver CE, Strojan P, Haigentz Jr M, Robbins KT, et al. The changing role of surgery in the current era of head and neck oncology. European archives of oto-rhino-laryngology. 2013;270(7):1971-3. 216.   Hartl DM, Brasnu DF, Shah JP, Hinni ML, Takes RP, Olsen KD, et al. Is open surgery for head and neck cancers truly declining? European archives of oto-rhino-laryngology. 2013;270(11):2793-802. 217.   van Loon Y, Sjögren EV, Langeveld TP, de Jong B, Rob J, Schoones JW, et al. Functional outcomes after radiotherapy or laser surgery in early glottic carcinoma: a systematic review. Head & neck. 2012;34(8):1179-89. 218.   Grégoire V, Hamoir M, Rosier J-F, Counoy H, Eeckhoudt L, Neymark N, et al. Cost-minimization analysis of treatment options for T1N0 glottic squamous cell carcinoma: comparison between external radiotherapy, laser microsurgery and partial laryngectomy. Radiotherapy and Oncology. 1999;53(1):1-13. 219.   Canis M, Ihler F, Martin A, Wolff HA, Matthias C, Steiner W. Organ preservation in T4a laryngeal cancer: is transoral laser microsurgery an option? European archives of oto-rhino-laryngology. 2013;270(10):2719-27. 220.   Canis M, Ihler F, Martin A, Wolff HA, Matthias C, Steiner W. Results of 226 patients with T3 laryngeal carcinoma after treatment with transoral laser microsurgery. Head & neck. 2014;36(5):652-9. 221.   Genden EM, O'Malley BW, Weinstein GS, Stucken CL, Selber JC, Rinaldo A, et al. Transoral robotic surgery: role in the management of upper aerodigestive tract tumors. Head & neck. 2012;34(6):886-93. 222.   Shah JP. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. The American journal of surgery. 1990;160(4):405-9. 223.   Machiels J-P, Lambrecht M, Hanin F-X, Duprez T, Gregoire V, Schmitz S, et al. Advances in the management of squamous cell carcinoma of the head and neck. F1000Prime Reports. 2014;6:44. 224.   Hamoir M, Fievez J, Schmitz S, Velasco D, Lengele B. Extended voice‐sparing surgery in selected pyriform sinus carcinoma: Techniques and outcomes. Head & neck. 2013;35(10):1482-9. 225.   Schmitz S, Machiels J-P, Weynand B, Gregoire V, Hamoir M. Results of selective neck dissection in the primary management of head and neck squamous cell carcinoma. European archives of oto-rhino-laryngology. 2009;266(3):437-43. 226.   Robbins KT, Ferlito A, Shah JP, Hamoir M, Takes RP, Strojan P, et al. The evolving role of selective neck dissection for head and neck squamous cell carcinoma. European archives of oto-rhino-laryngology. 2013;270(4):1195-202. 227.   Brizel DM, Prosnitz RG, Hunter S, Fisher SR, Clough RL, Downey MA, et al. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. International Journal of Radiation Oncology* Biology* Physics. 2004;58(5):1418-23. 228.   Argiris A, Stenson KM, Brockstein BE, Mittal BB, Pelzer H, Kies MS, et al. Neck dissection in the combined‐modality therapy of patients with locoregionally advanced head and neck cancer. Head & neck. 2004;26(5):447-55. 229.   Hamoir M, Ferlito A, Schmitz S, Hanin F-X, Thariat J, Weynand B, et al. The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease. Oral Oncology. 2012;48(3):203-10. 230.   Stenson KM, Huo D, Blair E, Cohen EE, Argiris A, Haraf DJ, et al. Planned Post‐Chemoradiation Neck Dissection: Significance of Radiation Dose. The Laryngoscope. 2006;116(1):33-6. 231.   Robbins KT, Wong FS, Kumar P, Hartsell WF, Vieira F, Mullins B, et al. Efficacy of targeted chemoradiation and planned selective neck dissection to control bulky nodal disease in advanced head and neck cancer. Archives of Otolaryngology–Head & Neck Surgery. 1999;125(6):670-5. 232.   Robbins KT, Doweck I, Samant S, Vieira F. Effectiveness of superselective and selective neck dissection for advanced nodal metastases after chemoradiation. Archives of Otolaryngology–Head & Neck Surgery. 2005;131(11):965-9. 233.   Mukhija V, Gupta S, Jacobson AS, Anderson Eloy J, Genden EM. Selective neck dissection following adjuvant therapy for advanced head and neck cancer. Head & neck. 2009;31(2):183-8. 234.   Dhiwakar M, Robbins KT, Vieira F, Rao K, Malone J. Selective neck dissection as an early salvage intervention for clinically persistent nodal disease following chemoradiation. Head & neck. 2012;34(2):188-93. 235.   Vermorken JB, Remenar E, Van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. New England Journal of Medicine. 2007;357(17):1695-704. 236.   Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. New England Journal of Medicine. 2007;357(17):1705-15. 237.   Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945-52. 238.   Kramer S, Gelber RD, Snow JB, Marcial VA, Lowry LD, Davis LW, et al. Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg. 1987;10(1):19-30. 239.   Parsons JT, Mendenhall WM, Stringer SP, Amdur RJ, Hinerman RW, Villaret DB, et al. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer. 2002;94(11):2967-80. 240.   Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, et al. Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer Patients. Cancer Prevention Research. 2009;2(9):776-81. 241.   Stevens KR, Britsch A, Moss WT. High-dose reirradiation of head and neck cancer with curative intent. International Journal of Radiation Oncology* Biology* Physics. 1994;29(4):687-98. 242.   Weppelmann B, Wheeler RH, Peters GE, Kim RY, Spencer SA, Meredith RF, et al. Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation. International Journal of Radiation Oncology* Biology* Physics. 1992;22(5):1051-6. 243.   Ang KK. Radiation injury to the central nervous system: clinical features and prevention.  Radiation Injury. 32: Karger Publishers; 1999. p. 145-54. 244.   Vokes E, Haraf D, Brockstein B, Weichselbaum R, editors. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Seminars in radiation oncology; 1999. 245.   Hong WK, Bromer R. Chemotherapy in head and neck cancer. New England Journal of Medicine. 1983;308(2):75-9. 246.   Spencer S, Harris J, Wheeler R, Machtay M, Schultz C, Spanos W, et al. RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. International Journal of Radiation Oncology* Biology* Physics. 2001;51(5):1299-304. 247.   Tanvetyanon T, Padhya T, McCaffrey J, Zhu W, Boulware D, DeConti R, et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer. Journal of Clinical Oncology. 2009;27(12):1983-91. 248.   Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun R-J, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. Journal of Clinical Oncology. 2008;26(34):5518-23. 249.   Argiris A. Induction chemotherapy for head and neck cancer: will history repeat itself? Journal of the National Comprehensive Cancer Network. 2005;3(3):393-403. 250.   Al-Sarraf M. Head and neck cancer: chemotherapy concepts. In Seminars in oncology. 1988 Feb;Vol. 15(1):70. 251.   Urba S, Forastiere A. Systemic therapy of head and neck cancer: most effective agents, areas of promise. Oncology (Williston Park, NY). 1989;3(4):79-88; discussion , 90, 7-8. 252.   Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Journal of Clinical Oncology. 2006;24(17):2644-52. 253.   Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, et al. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11(8):917-23. 254.   Blanchard P, Bourhis J, Lacas B, Posner M, Vermorken J, Hernandez J, et al. Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative GroupTaxane-Cisplatin-Fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 2013;31(23):2854-60. 255.   Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. The lancet oncology. 2013;14(3):257-64. 256.   Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. Journal of Clinical Oncology. 2014:JCO. 2013.54. 6309. 257.   Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. Jama. 2007;298(1):70-82. 258.   Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. The Lancet. 2008;371(9625):1695-709. 259.   Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine. 2006;354(6):567-78. 260.   Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. Journal of Clinical Oncology. 2014:JCO. 2013.53. 5633. 261.   Bernier  J, Domenge  C, Ozsahin  M, Matuszewska  K, Lefèbvre  J-L, Greiner  RH, et al. Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer. New England Journal of Medicine. 2004;350(19):1945-52. 262.   Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012;84(5):1198-205. 263.   Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27(10):843-50. 264.   Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, Daly-Schveitzer N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys. 1996;36(5):999-1004. 265.   Shah JP, Cendon RA, Farr HW, Strong EW. Carcinoma of the oral cavity. factors affecting treatment failure at the primary site and neck. Am J Surg. 1976;132(4):504-7. 266.   Looser KG, Shah JP, Strong EW. The significance of "positive" margins in surgically resected epidermoid carcinomas. Head Neck Surg. 1978;1(2):107-11. 267.   Johnson JT, Barnes EL, Myers EN, Schramm VL, Jr., Borochovitz D, Sigler BA. The extracapsular spread of tumors in cervical node metastasis. Arch Otolaryngol. 1981;107(12):725-9. 268.   Feldman M, Fletcher GH. Analysis of the parameters relating to failures above the clavicles in patients treated by postoperative irradiation for squamous cell carcinomas of the oral cavity or oropharynx. Int J Radiat Oncol Biol Phys. 1982;8(1):27-30. 269.   Mirimanoff RO, Wang CC, Doppke KP. Combined surgery and postoperative radiation therapy for advanced laryngeal and hypopharyngeal carcinomas. Int J Radiat Oncol Biol Phys. 1985;11(3):499-504. 270.   Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. International Journal of Radiation Oncology* Biology* Physics. 2001;51(3):571-8. 271.   Weissberg JB, Son YH, Papac RJ, Sasaki C, Fischer DB, Lawrence R, et al. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. International Journal of Radiation Oncology* Biology* Physics. 1989;17(1):3-9. 272.   Bachaud J-M, Cohen-Jonathan E, Alzieu C, David J-M, Serrano E, Daly-Schveitzer N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. International Journal of Radiation Oncology* Biology* Physics. 1996;36(5):999-1004. 273.   Weissler MC, Melin S, Sailer SL, Qaqish BF, Rosenman JG, Pillsbury HC. Simultaneous chemoradiation in the treatment of advanced head and neck cancer. Archives of Otolaryngology–Head & Neck Surgery. 1992;118(8):806-10. 274.   Weissberg JB, Son YH, Papac RJ, Sasaki C, Fischer DB, Lawrence R, et al. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. International Journal of Radiation Oncology* Biology* Physics. 1989;17(1):3-9. 275.   Weissberg JB, Son YH, Papac RJ, Sasaki C, Fischer DB, Lawrence R, et al. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. International Journal of Radiation Oncology* Biology* Physics. 1989;17(1):3-9. 276.   Haffty B  SY, Sasaki C , et al. . Mitomycin C as an adjunct to post-operative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials. Int J Radiat Oncol Biol Phys 1993;27(241-250). 277.   Bachaud J-M, Cohen-Jonathan E, Alzieu C, David J-M, Serrano E, Daly-Schveitzer N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. International Journal of Radiation Oncology* Biology* Physics. 1996;36(5):999-1004. 278.   Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre J-L, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. New England Journal of Medicine. 2004;350(19):1945-52. 279.   Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. New England Journal of Medicine. 2004;350(19):1937-44. 280.   Duvvuri U, Simental AA, Jr., D'Angelo G, Johnson JT, Ferris RL, Gooding W, et al. Elective neck dissection and survival in patients with squamous cell carcinoma of the oral cavity and oropharynx. Laryngoscope. 2004;114(12):2228-34. 281.   Jones AS, Fish B, Fenton JE, Husband DJ. The treatment of early laryngeal cancers (T1-T2 N0): surgery or irradiation? Head Neck. 2004;26(2):127-35. 282.   Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB. Management of T1-T2 glottic carcinomas. Cancer. 2004;100(9):1786-92. 283.   Dey P, Arnold D, Wight R, MacKenzie K, Kelly C, Wilson J. Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer. Cochrane Database Syst Rev. 2002;2. 284.   Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Malyapa RS, Werning JW, et al. Definitive radiotherapy for tonsillar squamous cell carcinoma. Am J Clin Oncol. 2006;29(3):290-7. 285.   Nakamura K, Shioyama Y, Kawashima M, Saito Y, Nakamura N, Nakata K, et al. Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy. International Journal of Radiation Oncology* Biology* Physics. 2006;65(4):1045-50. 286.   Nakamura K, Shioyama Y, Kawashima M, Saito Y, Nakamura N, Nakata K, et al. Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy. International Journal of Radiation Oncology* Biology* Physics. 2006;65(4):1045-50. 287.   Fletcher G, Jesse R, Lindberg R, Koons C. The place of radiotherapy in the management of the squamous cell carcinoma of the supraglottic larynx. American Journal of Roentgenology. 1970;108(1):19-26. 288.   Laramore GE, Scott CB, al-Sarraf M, Haselow RE, Ervin TJ, Wheeler R, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys. 1992;23(4):705-13. 289.   S̆mid L, Budihna M, Zakotnik B, S̆oba E, Strojan P, Fajdiga I, et al. Postoperative concomitant irradiation and chemotherapy with mitomycin C and bleomycin for advanced head-and-neck carcinoma. International Journal of Radiation Oncology* Biology* Physics. 2003;56(4):1055-62. 290.   Peters LJ, Goepfert H, Ang KK, Byers RM, Maor MH, Guillamondegui O, et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. International Journal of Radiation Oncology* Biology* Physics. 1993;26(1):3-11. 291.   Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. International Journal of Radiation Oncology* Biology* Physics. 2001;51(3):571-8. 292.   Cooper JS, Pajak TF, Forastiere A, Jacobs J, Fu KK, Ang KK, et al. Precisely defining high‐risk operable head and neck tumors based on rtog# 85‐03 and# 88‐24: Targets for postoperative radiochemotherapy? Head & neck. 1998;20(7):588-94. 293.   Bernier J, Cooper JS, Pajak T, Van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (# 22931) and RTOG (# 9501). Head & neck. 2005;27(10):843-50. 294.   Langendijk JA, Slotman BJ, van der Waal I, Doornaert P, Berkof J, Leemans CR. Risk‐group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy. Cancer. 2005;104(7):1408-17. 295.   Soo KC, Carter RL, O'Brien CJ, Barr L, Bliss JM, Shaw HJ. Prognostic implications of perineural spread in squamous carcinomas of the head and neck. The Laryngoscope. 1986;96(10):1145-8. 296.   Kotwall C, Sako K, Razack MS, Rao U, Bakamjian V, Shedd DP. Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg. 1987;154(4):439-42. 297.   Pigott K, Dische S, Saunders MI. Where exactly does failure occur after radiation in head and neck cancer? Radiother Oncol. 1995;37(1):17-9. 298.   Langlois D, Eschwege F, Kramar A, Richard J. Reirradiation of head and neck cancers: Presentation of 35 cases treated at the Gustave Roussy Institute. Radiotherapy and Oncology. 1985;3(1):27-33. 299.   Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007;25(30):4800-5. 300.   Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30(3):281-8. 301.   Yom S, Ganti A, Dietz A, editors. What's New in Head and Neck Cancer: Key Findings in 2015-2016 From ECCO/ESMO, ASTRO, and the Multidisciplinary Head and Neck Cancer Symposium. American Society of Clinical Oncology educational book/ASCO American Society of Clinical Oncology Meeting; 2015. 302.   Browman GP, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. Semin Oncol. 1994;21(3):311-9. 303.   Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer. 1985;55(5):1123-8. 304.   Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10(8):1245-51. 305.   Merlano MC, Monteverde M, Colantonio I, Denaro N, Nigro CL, Natoli G, et al. Impact of age on acute toxicity induced by bio-or chemo-radiotherapy in patients with head and neck cancer. Oral Oncology. 2012;48(10):1051-7. 306.   Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. New England Journal of Medicine. 2010;363(1):24-35. 307.   Koness RJ, Glicksman A, Liu L, Coachman N, Landman C, Slotman G, et al. Recurrence patterns with concurrent platinum-based chemotherapy and accelerated hyperfractionated radiotherapy in stage III and IV head and neck cancer patients. The American journal of surgery. 1997;174(5):532-5. 308.   Vokes EE, Kies MS, Haraf DJ, Stenson K, List M, Humerickhouse R, et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. Journal of Clinical Oncology. 2000;18(8):1652-61. 309.   Kies MS, Haraf DJ, Rosen F, Stenson K, List M, Brockstein B, et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. Journal of Clinical Oncology. 2001;19(7):1961-9. 310.   Adelstein DJ, Saxton JP, Lavertu P, Rybicki LA, Esclamado RM, Wood BG, et al. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. Journal of Clinical Oncology. 2002;20(5):1405-10. 311.   Wong LY, Wei WI, Lam LK, Yuen APW. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head & neck. 2003;25(11):953-9. 312.   Bloom C, Just N, Remy H, Black M, Rossignol M. Laryngeal cancer: is computed tomography a valuable imaging technique? A retrospective analysis. Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes. 1998;49(6):370-7. 313.   Kuperman DI, Auethavekiat V, Adkins DR, Nussenbaum B, Collins S, Boonchalermvichian C, et al. Squamous cell cancer of the head and neck with distant metastasis at presentation. Head & neck. 2011;33(5):714-8. 314.   Alvi A, Johnson JT. Development of distant metastasis after treatment of advanced‐stage head and neck cancer. Head & neck. 1997;19(6):500-5. 315.   Nishijima W, Takooda S, Tokita N, Takayama S, Sakura M. Analyses of distant metastases in squamous cell carcinoma of the head and neck and lesions above the clavicle at autopsy. Archives of Otolaryngology–Head & Neck Surgery. 1993;119(1):65-8. 316.   Zbären P, Lehmann W. Frequency and sites of distant metastases in head and neck squamous cell carcinoma: an analysis of 101 cases at autopsy. Archives of Otolaryngology–Head & Neck Surgery. 1987;113(7):762-4. 317.   León X, Quer M, Orús C, del Prado Venegas M, López M. Distant metastases in head and neck cancer patients who achieved loco‐regional control. Head & neck. 2000;22(7):680-6. 318.   Garavello W, Ciardo A, Spreafico R, Gaini RM. Risk factors for distant metastases in head and neck squamous cell carcinoma. Archives of Otolaryngology–Head & Neck Surgery. 2006;132(7):762-6. 319.   Calhoun KH, Fulmer P, Weiss R, Hokanson JA. Distant metastases from head and neck squamous cell carcinomas. The Laryngoscope. 1994;104(10):1199-205. 320.   Li X, Di B, Shang Y, Zhou Y, Cheng J, He Z. Clinicopathologic risk factors for distant metastases from head and neck squamous cell carcinomas. European Journal of Surgical Oncology (EJSO). 2009;35(12):1348-53. 321.   Langley RR, Fidler IJ. The seed and soil hypothesis revisited—The role of tumor‐stroma interactions in metastasis to different organs. International journal of cancer. 2011;128(11):2527-35. 322.   Jackel MC, Rausch H. [Distant metastasis of squamous epithelial carcinomas of the upper aerodigestive tract. The effect of clinical tumor parameters and course of illness]. Hno. 1999;47(1):38-44. 323.   De Bree R, Mehta DM, Snow GB, Quak JJ. Intracranial metastases in patients with squamous cell carcinoma of the head and neck. Otolaryngology--Head and Neck Surgery. 2001;124(2):217-21. 324.   Pitman KT, Johnson JT. Skin metastases from head and neck squamous cell carcinoma: incidence and impact. Head & neck. 1999;21(6):560-5. 325.   Schwartz RA. Cutaneous metastatic disease. J Am Acad Dermatol. 1995;33(2 Pt 1):161-82. 326.   Koch WM. Axillary nodal metastases in head and neck cancer. Head Neck. 1999;21(3):269-72. 327.   Slaughter DP, Southwick HW, Smejkal W. “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer. 1953;6(5):963-8. 328.   Taneja C, Allen H, Koness RJ, Radie-Keane K, Wanebo HJ. Changing patterns of failure of head and neck cancer. Archives of Otolaryngology–Head & Neck Surgery. 2002;128(3):324-7. 329.   Helliwell T, Woolgar J. Royal College of Pathologists standards and datasets for reporting cancers. Royal College of Pathologists, London. 2011. 330.   Ozdek A, Sarac S, Akyol MU, Unal OF, Sungur A. Histopathological predictors of occult lymph node metastases in supraglottic squamous cell carcinomas. European archives of oto-rhino-laryngology. 2000;257(7):389-92. 331.   Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96. 332.   Howell GM, Grandis JR. Molecular mediators of metastasis in head and neck squamous cell carcinoma. Head Neck. 2005;27(8):710-7. 333.   Dunne AA, Muller HH, Eisele DW, Kessel K, Moll R, Werner JA. Meta-analysis of the prognostic significance of perinodal spread in head and neck squamous cell carcinomas (HNSCC) patients. Eur J Cancer. 2006;42(12):1863-8. 334.   Cady B. Lymph node metastases. Indicators, but not governors of survival. Arch Surg. 1984;119(9):1067-72. 335.   Leong SP, Cady B, Jablons DM, Garcia-Aguilar J, Reintgen D, Jakub J, et al. Clinical patterns of metastasis. Cancer Metastasis Rev. 2006;25(2):221-32. 336.   Richard JM, Sancho-Garnier H, Micheau C, Saravane D, Cachin Y. Prognostic factors in cervical lymph node metastasis in upper respiratory and digestive tract carcinomas: study of 1,713 cases during a 15-year period. Laryngoscope. 1987;97(1):97-101. 337.   Chen TY, Emrich LJ, Driscoll DL. The clinical significance of pathological findings in surgically resected margins of the primary tumor in head and neck carcinoma. Int J Radiat Oncol Biol Phys. 1987;13(6):833-7. 338.   Looser KG, Shah JP, Strong EW. The significance of “positive” margins in surgically resected epidermoid carcinomas. Head & neck surgery. 1978;1(2):107-11. 339.   Martin SA, Marks JE, Lee JY, Bauer WC, Ogura JH. Carcinoma of the pyriform sinus: predictors of TNM relapse and survival. Cancer. 1980;46(9):1974-81. 340.   Rapoport A, Franco EL. Prognostic factors and relative risk in hypopharyngeal cancer--related parameters concerning stage, therapeutics and evolution. Revista paulista de medicina. 1992;111(2):337-43. 341.   Janssen-Heijnen M, Nab H, Van Reek J, Van der Heijden L, Schipper R, Coebergh J. Striking changes in smoking behaviour and lung cancer incidence by histological type in Southeast Netherlands, 1960–1991. European Journal of Cancer. 1995;31(6):949-52. 342.   Mak-Kregar S, Hilgers F, Levendag P, Manni J, Lubsen H, Roodenburg J, et al. A nationwide study of the epidemiology, treatment and survival of oropharyngeal carcinoma in the Netherlands. European archives of oto-rhino-laryngology. 1995;252(3):133-8. 343.   Mork J, Glattre E. Squamous cell carcinomas of the head and neck in Norway, 1953-92: an epidemiologic study of a low-risk population. Cancer Causes & Control. 1998;9(1):37-48. 344.   Worrall SF. An audit of general dental practitioners' referral practice following the distribution of third molar guidelines. Annals of The Royal College of Surgeons of England. 2001;83(1):61-4. 345.   Coleman M, Gatta G, Verdecchia A, Esteve J, Sant M, Storm H, et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Annals of oncology. 2003;14(suppl 5):v128-v49. 346.   Wang B, Zhang S, Yue K, Wang X-D. The recurrence and survival of oral squamous cell carcinoma: a report of 275 cases. Chinese Journal of Cancer. 2013;32(11):614-8. 347.   Ozturk K, Gode S, Erdogan U, Akyildiz S, Apaydin F. Squamous cell carcinoma of the lip: survival analysis with long-term follow-up. European Archives of Oto-Rhino-Laryngology. 2015;272(11):3545-50. 348.   Chen P-H, Shieh T-Y, Ho P-S, Tsai C-C, Yang Y-H, Lin Y-C, et al. Prognostic factors associated with the survival of oral and pharyngeal carcinoma in Taiwan. BMC Cancer. 2007;7(1):1-11. 349.   Tian WD, Zeng ZY, Chen FJ, Wu GH, Guo ZM, Zhang Q. [Treatment and prognosis of stage III-IV laryngeal squamous cell carcinoma]. Ai zheng = Aizheng = Chinese journal of cancer. 2006;25(1):80-4. 350.   Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758-65. 351.   Kowalski LP, Alcantara PS, Magrin J, Parise Júnior O. A case-control study on complications and survival in elderly patients undergoing major head and neck surgery. American journal of surgery. 1994;168(5):485-90. 352.   Clayman GL, Eicher SA, Sicard MW, Razmpa E, Goepfert H. Surgical outcomes in head and neck cancer patients 80 years of age and older. Head Neck. 1998;20(3):216-23. 353.   Laccourreye O, Brasnu D, Perie S, Muscatello L, Menard M, Weinstein G. Supracricoid partial laryngectomies in the elderly: mortality, complications, and functional outcome. Laryngoscope. 1998;108(2):237-42. 354.   McGuirt WF, Davis SP, 3rd. Demographic portrayal and outcome analysis of head and neck cancer surgery in the elderly. Arch Otolaryngol Head Neck Surg. 1995;121(2):150-4. 355.   Pignon T, Horiot JC, Van den Bogaert W, Van Glabbeke M, Scalliet P. No age limit for radical radiotherapy in head and neck tumours. Eur J Cancer. 1996;32a(12):2075-81. 356.   Allal AS, Maire D, Becker M, Dulguerov P. Feasibility and early results of accelerated radiotherapy for head and neck carcinoma in the elderly. Cancer. 2000;88(3):648-52. 357.   Huang SH, O'Sullivan B, Waldron J, Lockwood G, Bayley A, Kim J, et al. Patterns of care in elderly head-and-neck cancer radiation oncology patients: a single-center cohort study. Int J Radiat Oncol Biol Phys. 2011;79(1):46-51. 358.   Merlano MC, Monteverde M, Colantonio I, Denaro N, Lo Nigro C, Natoli G, et al. Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer. Oral Oncol. 2012;48(10):1051-7. 359.   Morgan RF, Hirata RM, Jaques DA, Hoopes JE. Head and neck surgery in the aged. Am J Surg. 1982;144(4):449-51. 360.   Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis. Journal of Clinical Oncology. 2008;26(21):3582-9. 361.   Boute P, Page C, Biet A, Cuvelier P, Strunski V, Chevalier D. Epidemiology, prognosis and treatment of simultaneous squamous cell carcinomas of the oral cavity and hypopharynx. Eur Ann Otorhinolaryngol Head Neck Dis. 2014;131(5):283-7. 362.   Baatenburg de Jong RJ, Hermans J, Molenaar J, Briaire JJ, le Cessie S. Prediction of survival in patients with head and neck cancer. Head & Neck. 2001;23(9):718-24. 363.   McDonald JT, Johnson-Obaseki S, Hwang E, Connell C, Corsten M. The relationship between survival and socio-economic status for head and neck cancer in Canada. Journal of Otolaryngology-Head & Neck Surgery. 2014;43(1):1. 364.   Boyd C, Zhang-Salomons JY, Groome PA, Mackillop WJ. Associations between community income and cancer survival in Ontario, Canada, and the United States. Journal of Clinical Oncology. 1999;17(7):2244-. 365.   Andersen ZJ, Lassen CF, Clemmensen IH. Social inequality and incidence of and survival from cancers of the mouth, pharynx and larynx in a population-based study in Denmark, 1994–2003. European Journal of Cancer. 2008;44(14):1950-61. 366.   Sabik LM, Bradley CJ. Differences in Mortality for Surgical Cancer Patients by Insurance and Hospital Safety Net Status. Medical care research and review : MCRR. 2013;70(1):84-97. 367.   Takenaka Y, Yasui T, Enomoto K, Miyabe H, Morizane N, Ashida N, et al. Health insurance status and survival among patients with head and neck cancer in Japan. International journal of clinical oncology. 2015:1-6. 368.   Colevas AD. Population‐based evaluation of incidence trends in oropharyngeal cancer focusing on socioeconomic status, sex, and race/ethnicity. Head & neck. 2014;36(1):34-42. 369.   Choi SH, Terrell JE, Fowler KE, McLean SA, Ghanem T, Wolf GT, et al. Socioeconomic and Other Demographic Disparities Predicting Survival among Head and Neck Cancer Patients. PloS one. 2016;11(3):e0149886. 370.   Steenland K, Henley J, Thun M. All-Cause and Cause-specific Death Rates by Educational Status for Two Million People in Two American Cancer Society Cohorts, 1959–1996. American Journal of Epidemiology. 2002;156(1):11-21. 371.   Freeman HP. Cancer in the socioeconomically disadvantaged. CA Cancer J Clin. 1989;39(5):266-88. 372.   Mehta R, Gillan AS, Ming ZY, Rai BP, Byrne D, Nabi G. Socio-economic deprivation and outcomes following radical nephroureterectomy for clinically localized upper tract transitional cell carcinoma. World Journal of Urology. 2015;33(1):41-9. 373.   Leemans CR, Tiwari R, Nauta JJ, Waal IVD, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer. 1994;73(1):187-90. 374.   Pruegsanusak K, Peeravut S, Leelamanit V, Sinkijcharoenchai W, Jongsatitpaiboon J, Phungrassami T, et al. Survival and prognostic factors of different sites of head and neck cancer: an analysis from Thailand. Asian Pacific Journal of Cancer Prevention. 2012;13(3):885-90. 375.   Kim D-Y, Roh J-L, Choi JW, Choi S-H, Nam SY, Kim SY. Risk factors and survival outcomes for patients with anastomotic leakage after surgery for head and neck squamous cell carcinoma. Clinical and experimental otorhinolaryngology. 2014;7(1):36-41. 376.   Zhang H, Dziegielewski PT, Nguyen TJ, Jeffery CC, O’Connell DA, Harris JR, et al. The effects of geography on survival in patients with oral cavity squamous cell carcinoma. Oral oncology. 2015;51(6):578-85. 377.   Sargeran K. Treatment delay among oral cancer patients in Tehran, Iran. Journal of Craniomaxillofacial Research. 2015;1(2):37-41. 378.   Deutschmann MW, Sykes KJ, Harbison J, Cabrera-Muffly C, Shnayder Y. The impact of compliance in posttreatment surveillance in head and neck squamous cell carcinoma. JAMA Otolaryngology–Head & Neck Surgery. 2015;141(6):519-25. 379.   Le Tourneau C, Velten M, Jung GM, Bronner G, Flesch H, Borel C. Prognostic indicators for survival in head and neck squamous cell carcinomas: analysis of a series of 621 cases. Head & neck. 2005;27(9):801-8. 380.   Gamel JW, Jones AS. Squamous carcinoma of the head and neck: cured fraction and median survival time as functions of age, sex, histologic type, and node status. British Journal of Cancer. 1993;67(5):1071-5. 381.   Haas I, Hauser U, Ganzer U. The dilemma of follow-up in head and neck cancer patients. European archives of oto-rhino-laryngology. 2001;258(4):177-83. 382.   Kowalski LP, Carvalho AL, Martins Priante AV, Magrin J. Predictive factors for distant metastasis from oral and oropharyngeal squamous cell carcinoma. Oral Oncology. 2005;41(5):534-41. 383.   Böscke R, Cakir BD, Hoffmann AS, Wiegand S, Quetz J, Meyer JE. Outcome after elective neck dissection and observation for the treatment of the clinically node-negative neck (cN0) in squamous cell carcinoma of the oropharynx. European Archives of Oto-Rhino-Laryngology. 2014;271(3):567-74. 384.   Lester S, Wight R. ‘When will I see you again?’Using local recurrence data to develop a regimen for routine surveillance in post‐treatment head and neck cancer patients. Clinical Otolaryngology. 2009;34(6):546-51. 385.   Leemans CR, Tiwari R, Nauta JJ, Waal IVD, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer. 1994;73(1):187-90. 386.   Moore SP, Green AC, Garvey G, Coory MD, Valery PC. A study of head and neck cancer treatment and survival among indigenous and non-indigenous people in Queensland, Australia, 1998 to 2004. BMC cancer. 2011;11(1):1. 387.   Sanabria A, Carvalho AL, Vartanian JG, Magrin J, Ikeda MK, Kowalski LP. Comorbidity Is a Prognostic Factor in Elderly Patients with Head and Neck Cancer. Annals of Surgical Oncology. 2007;14(4):1449-57. 388.   Lassig AA, Joseph AM, Lindgren BR, Fernandes P, Cooper S, Schotzko C, et al. The effect of treating institution on outcomes in head and neck cancer. Otolaryngol Head Neck Surg. 2012;147(6):1083-92. 389.   Fan Y, Zheng L, Mao M-H, Huang M-W, Liu S-M, Zhang J, et al. Survival analysis of oral squamous cell carcinoma in a subgroup of young patients. Asian Pac J Cancer Prev. 2014;15(20):8887-91. 390.   Hoffmann M, Saleh-Ebrahimi L, Zwicker F, Haering P, Schwahofer A, Debus J, et al. Long term results of postoperative Intensity-Modulated Radiation Therapy (IMRT) in the treatment of Squamous Cell Carcinoma (SCC) located in the oropharynx or oral cavity. Radiation Oncology. 2015;10(1):1. 391.   Givi B, Eskander A, Awad MI, Kong Q, Montero PH, Palmer FL, et al. Impact of elective neck dissection on the outcome of oral squamous cell carcinomas arising in the maxillary alveolus and hard palate. Head & neck. 2015. 392.   Woolgar J, Rogers S, West C, Errington R, Brown J, Vaughan E. Survival and patterns of recurrence in 200 oral cancer patients treated by radical surgery and neck dissection. Oral oncology. 1999;35(3):257-65. 393.   Lo W-L, Kao S-Y, Chi L-Y, Wong Y-K, Chang RC-S. Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. Journal of oral and maxillofacial surgery. 2003;61(7):751-8. 394.   Charabi S, Balle V, Charabi B, Berthelsen A, Thomsen J. Squamous cell carcinoma of the oral cavity: the results of the surgical and non-surgical therapeutic modalities in a consecutive series of 156 patients treated in Copenhagen county. Acta Oto-Laryngologica. 1997;117(sup529):226-8. 395.   Freier K, Engel M, Lindel K, Flechtenmacher C, Mühling J, Hassfeld S, et al. Neoadjuvant concurrent radiochemotherapy followed by surgery in advanced oral squamous cell carcinoma (OSCC): a retrospective analysis of 207 patients. Oral oncology. 2008;44(2):116-23. 396.   Ma'aita JK. Oral cancer in Jordan: a retrospective study of 118 patients. Croatian medical journal. 2000;41(1):64-9. 397.   Rao D, Shroff P, Chattopadhyay G, Dinshaw K. Survival analysis of 5595 head and neck cancers--results of conventional treatment in a high-risk population. British journal of cancer. 1998;77(9):1514. 398.   <http://www.cancer.ca/Canadawide/About%20cancer/Cancer%20statistics.aspxsc_lang=en>; CCSoC. 2011[accessed 01.03.13].


منبع:پورتال دانشکده

نظرات
5/5 0 0 0